ExpiresDecember 7, 2019
University of South Florida Health
Pain continues to be a significant public-health problem in the US, causing significant reductions in patients’ quality of life. Despite the pain-relieving properties of opioid medications, patients with acute and chronic pain are often undertreated due to a variety of physician- and patient-related concerns and barriers, including the potential for misuse and abuse.
The Food and Drug Administration (FDA) developed the Risk Evaluation and Mitigation Strategy (REMS) to ensure the benefits outweigh the risks with opioid treatments. The FDA Blueprint was recently updated to include more information on pain management, including components of an effective treatment plan,
nonpharmacologic and pharmacologic treatments for pain (nonopioid and opioid analgesics), and a primer on addiction medicine. The updated blueprint applies not only to prescribers, but to all healthcare providers involved in the management of patients with acute and chronic pain.
Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS) incorporates the updated FDA blueprint into practical education designed to help clinicians improve the quality of care and reduce the pain of their patients.
ABMS Member Board Approvals by Type
ABMS MOC Part II Self-Assessment Activity
Physical Medicine and Rehabilitation
ABMS MOC Part II CME Activity
Psychiatry and Neurology
NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
-Identify risk factors and vulnerabilities associated with addiction to opioid analgesics and provide patient/caregiver counselling when necessary
-Discuss the components of an effective treatment plan, including patient interactions, treatment goals, and collaboration within the healthcare team
-Analyze the specific benefits and risks to initiating non-medication therapies before utilizing long-term medications
-Recognize patients who are candidates for treatment with nonopioid pharmacologic analgesics
-Explain the decision to initiate long-term opioid analgesics, including ER/LA opioids, with consideration to providing in-home naloxone
-Determine when referral to a pain specialist is appropriate for a patient with chronic pain
Opioid therapy, Pain management, Substance use disorder, Multimodal
Medical Knowledge, Patient Care & Procedural Skills, Practice-based Learning & Improvement, Systems-based Practice
CME Credit Type
AAFP Prescribed Credit, AMA PRA Category 1 Credit
This educational activity is supported by an independent educational grant from the Extended-Release/Long-Acting Opioid Analgesic REMS Program Companies.
Outpatient, Physician Scientists, Rural, Urban